Concepedia
Statistics
Publications
3
Citations
206
H-Index
Active since
2020
Affiliations
MacroGenics (United States)(Current)
The University of Texas MD Anderson Cancer Center
BioVirtus (Poland)
Tennessee Oncology
Banner MD Anderson Cancer Center
Bradley Sumrow is an author at MacroGenics (United States) specializing in immunotherapy, cancer immunotherapy, and oncology.
Publications per year
2020–2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
Jason J. Luke, Manish R. Patel, George R. Blumenschein et al. · Nature Medicine · 2023 · 128 citations · Full text
Medicine, Oncology, Pharmacology +17
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
Alexey Berezhnoy, Bradley Sumrow, Kurt Stahl et al. · Cell Reports Medicine · 2020 · 53 citations · Full text
Life Sciences, Immunology, Oncology +17
A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Jie Wang, Adam S. Asch, Nada Hamad et al. · Blood · 2020 · 25 citations
Medicine, Oncology, Pharmacology +15
1–3 of 3